Novartis CEO: 'Europe Lags Behind' On Innovation

2026-01-20 02:09:29

(MENAFN- Swissinfo) Novartis CEO Vasant Narasimhan told Bloomberg in an interview that he sees clear differences between Europe and the US in the Swiss pharmaceutical giant's investment strategy. This content was published on January 20, 2026 - 17:56 2 minutes Keystone-SDA

Italiano it Novartis:“l'Europa resta indietro, priorità a investimenti Usa” Original Read more: Novartis:“l'Europa resta indietro, priorità a investimenti

+ Get the most important news from Switzerland in your inbox

The investment environment outside Europe is currently“much more favourable”, Narasimhan said in the interview with Bloomberg on the sidelines of the World Economic Forum in Davos.

The statement comes against a backdrop of renewed geopolitical uncertainties and trade tensions, challenges that are particularly relevant for an industry with innovation cycles in excess of ten years. Although these“instabilities” should not be underestimated, according to Narasimhan they do not undermine Novartis' business model.
More More Global trade US 'strikes price cut deal' with Swiss pharma giants
This content was published on Dec 18, 2025 US reportedly strikes deal with Swiss pharmaceutical giants Novartis and Roche to lower drug prices.
Read more: US 'strikes price cut deal' with Swiss pharma g

MENAFN20012026000210011054ID1110626232

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.